The antibody reacts specificly with Human IL-1RII. The IL-1 system includes two agonists (IL-1alpha and IL-1beta), converting enzymes, antagonists, two receptors (IL-1RI and IL-1RII) and the IL-1 receptor accessory protein. The IL-1RII is part of the antagonistic IL-1 mechanism. It is also known as decoy receptor and is a non signaling molecule which functions by capturing IL-1 and preventing it from interacting with the signalling IL-1RI. The decoy IL-1RII can after binding to IL-1 also recruit the IL-1 receptor accessory protein and thus inhibit by coreceptor competition. Further a soluble form of IL-1RII exists which is shed, a process in which matrix metalloproteases have been found to play a role, by various cells including monocytes, polymorphonuclear cells, B cells and fibroblasts.
Antibody Isotype:
IgG1
Monosan Range:
MONOSAN
Clone:
8.5
Concentration:
100 ug/ ml
Storage buffer:
PBS with 0.1% BSA and 0.02% sodium azide
Storage:
2-8°C
References 1:
Mantovani; A et al. Ann N Y Acad Sci 1998; 840: 338
The monoclonal antibody M.Ab.F11 recognizes junctional adhesion molecule-A (JAM-A) also known as the human platelet F11-Receptor (F11R) or JAM-1. JAM-A is a surface glycoprotein duplex (32 and 35 kDa) belongingto the immunoglobulin superfamily found on the surface of human platelets and at intercellular junctions of endothelial cells and epithelial cells. JAM-A belongs together with JAM-C (JAM-2) and JAM-B (VE-JAM or JAM-3) to a family of adhesion proteins with a V-C2 immunoglobulin domain organization. JAM-A plays an important role in tight junctions where it is involved in cell-to-cell adhesion through homophilic interactions. It co-distributes with other tight junction components such as ZO-1, 7H6 antigen, cingulin and occludin. Moreover, JAM-A plays a role in platelet aggregation, secretion, adhesion, spreading.<br /> In the platelet, JAM-A is a membrane protein involved in 2 distinct processes initiated on the platelet surface. Namely,, antibody-induced platelet aggregation and secretion both dependent on FcgammaRII and GPIIb/IIIa integrin, a process that may be involved in pathophysiological processes associated with certain thrombocytopenias and secondly, antibody mediated platelet adhesion independent from FcgammaRII or- fibrinogen receptor that appears to play a role in physiological processes associated with platelet adhesion and aggregation. A physiological role for the JAM-A protein was demonstrated by its phosphorylation after the stimulation of platelets by thrombin and collagen. A pathophysiological role for the JAM-A was revealed by demonstrating the presence of JAM-A antibodies in patients with thrombocytopenia. Adhesion of platelets through JAM-A resulted in events characteristic of the action of cell adhesion molecules. Recent data suggests a role for JAM-A in the adhesion of platelets to cytokine-inflamed endothelial cells and thus in thrombosis and atherosclerosis induced in non-denuded blood vessels by inflammatory processes.
LN-5 reacts with human macrophages and displays lymph node germinal center and mantle zone B cell reactivity. It reacts with interdigitating reticulum cells, with tingible body and sinus histiocytes. It further reacts with certain tumor cells and also with normal nonlymphoid tissue like chief cells of the stomach and spermatogonia. LN-5 is negative on Hodgkins disease and non-Hodgkins lymphomas.
EBS-T-005 reacts with MADER or Melanoma-Associated Delayed Early Response protein, encoded by the NAB2 gene, belonging to the family of NGFI-A binding proteins. They modulate transcription induced by some members of the EGR (early growth response) family of transactivators. NAB proteins can form homo- or hetero-multimers with other EGR or NAB proteins through a conserved N-terminal domain, and repress transcription through two partially redundant C-terminal domains.
This antibody stains a minority of primary melanomas and half of the metastatic lesions tested. It rarely stains dysplastic naevi or common cellular naevi using standard immunohistochemical conditions. The antibody recognizes two protein bands in immunoblotting with a molecular weight of 95-100 kD.
Antibody Isotype:
IgG1
Monosan Range:
MONOSAN
Clone:
PAL-M2
Concentration:
10 ug/ml
Storage buffer:
Culture medium with 0.01M Sodium Azide
Storage:
2-8°C
References 1:
Ruiter DJ et al., (1985) J Invest Dermatol 85, 4-8
108-2C5 recognizes an intralocus determinant present on a limited number of HLA-A locusencoded gene products (HLA-A2, -A3, A28, -A29, -A30, -A31 and -Aw33). Furthermore, by testing its reactivity with HLA-A2 natural variants and mutants, the importance of amino acid residues 79 and/or 80 of the alpha1 domain was demonstrated in the formation of an intralocus HLA-A determinant.
Antibody Isotype:
IgG1-K
Monosan Range:
MONOSAN
Clone:
108-2C5
Concentration:
100 ug/ml
Storage buffer:
PBS with 0.02% sodium azide
Storage:
2-8°C
References 1:
Lozano, F. et al., Immunogenetics 30: 50-53 (1989)
References 2:
Lozano, F. et al., Tissue Antigens 35: 193-195 (1990)
References 3:
Domenech, N. et al., Human Immunol 30: 140-146 (1991)
References 4:
Ryschich, E, et al, Clin Cancer Res. 11(2 Pt 1): 498-504 (2005)
The antibody reacts with an internal epitope of MRP1, a 180-195 kD transmembrane transporter protein overexpressed in various human non-P-glycoprotein MDR tumor cell lines. MRPm5 was raised against a bacterial fusion protein of MRP1, containing amino acids 986-1204 of the protein. MRPm5 does not cross-react with the human MDR1 and MDR3 gene products.
Antibody Isotype:
IgG2a
Monosan Range:
MONOSAN
Clone:
MRPm5
Concentration:
100 ug/ ml
Format:
Protein G purified
Storage buffer:
PBS with 0.1% BSA and 0.02% sodium azide
Storage:
2-8°C
References 1:
Cole S et al. Science 1992; 258: 1650-1654
References 2:
Flens M et al. Cancer Res 1994; 54: 4557-4563
References 3:
Zaman et al. Proc Nat Acad Sci 1994; 91: 8822-8826
VU-4H5 reacts with the protein core of MUC1, an apical cell side epithelial marker which is upregulated or switched on in the majority of carcinomas. The dominant epitope of VU-4H5 is PDTR, located in the VNTR domain of MUC1. In tissue sections, VU-4H5 also displays prominent staining of the cytoplasm.
BM-5 is specific marker for human myeloid cells and an early marker of myeloid differentiation. It recognizes a nuclear and cytoplasmic antigen present in granulocytes, monocytes, and myeloid precursor cells. It also reacts with a subset of myeloid leukemia cells. BM-5 has no reactivity with any other cell type in human tissues.
UACA (Uveal Autoantigen with Coiled-coil domains and Ankyrin repeats) is a 1,416 amino acid nuclear membrane protein. It was originally identified as an autoantigen in patients with panuveitis, a characteristic of Vogt-Koyanagi-Harada disease, and in patients with Graves' disease. UACA was also later identified as Nucling, a mRNA differentially expressed in F9 embryonal carcinoma cells, and that is up-regulated during cardiac muscle differentiation. UACA appears to function as a pro-apoptotic protein that recruits the apaf-1- pro-caspase-9 complex for the induction of apoptosis to mediate the cell-death pathway.
Antibody Isotype:
IgG1,kappa
Monosan Range:
MONOSAN
Clone:
AE-5
Concentration:
100 ug/ml
Storage buffer:
PBS with 0.02% sodium azide
Storage:
2-8°C
References 1:
Yamada, K., et al. Biochem. Biophys. Res. Commun. 280: 1169-1176 (2001)
PN-15 reacts with a lectin receptor like glycoprotein of 200 kDa (gp200), present in proximal renal tubules and on urothelium. The antigen is carbohydrate in nature. Other normal tissues that display the antigen include breast, parathyroid glands, thymus and epididymis. Among renal carcinomas 93% of primary and 84% of metastatic carcinomas are positive. Bladder cancers are also largely positive. Other tumor types include breast cancer, teratocarcinomas and parathyroid adenomas. The antigen, also called DEC-205, was assigned to CD205 at CD workshop VII. In the immune system it can facilitate tolerance to self-antigens through uptake of apoptosis derived material by dendritic cells, which in turn present fragments through MHC II and MHC I, either inducing or repressing immune responses, depending on the nature of concomitant signals.
Antibody Isotype:
IgG2b-kappa
Monosan Range:
MONOSAN
Clone:
PN-15
Concentration:
100 ug/ml
Storage buffer:
PBS with 0.02% sodium azide
Storage:
2-8°C
References 1:
Yoshida, S.O. et al, Cancer Res 49: 1802-1809 (1989)
References 2:
Li, G, et al, Anticancer Res. 20(4): 2773-8 (2000)
References 3:
Batchelder C.A. et al, Anat Rec (Hoboken) 297(8): 1392-1406 (2014)
References 4:
Cykowski M.D. et al, Ultrastruct Pathol 39(1): 69-77 (2015)
The monoclonal antibody recognizes rat CD8 antigen (MW 34 kDa and 39 kDa) and is reactive with all common inbred strains. 15-11C5 is derived from hybridization of mouse SP2/0 myeloma cells with spleen cells from Balb/c mice immunized with WAG/Rij spleen cells.
58-15 Recognizes riboncleoproteins (RNP), found predominantly in nuclear ribonucleoprotein (nRNP) particles, one of the main components of nucleoli. It identifies cells active in the cell cycle and hence can be used to measure the mitotic activity of cell populations. Since the antibody can be used in paraffin embedded tissue sections, it can identify actively cycling cells within routinely fixed tissue specimens. 58-15 Can be considered a pan nRNP antibody. Pan nRNP antibodies provide detection for a range of RNP proteins.
Antibody Isotype:
IgM
Monosan Range:
MONOSAN
Clone:
58-15
Concentration:
100 ug/ml
Storage buffer:
PBS with 0.02% sodium azide
Storage:
2-8°C
References 1:
Clevenger, C.V. et al. J Histochem Cytochem 32: 757-765 (1984)
References 2:
Clevenger, C.V. et al. Cytometry 6: 208-214 (1985)
References 3:
Maryam A and Nigel WF, J Virol. 75: 12070-12080, (2001)
SV40, Simian Virus 40 is a polyomavirus that is found in both monkeys and humans. Like other polyomaviruses, SV40 is a DNA virus that has the potential to cause tumors. SV40 is believed to suppress the transcriptional properties of tumor-suppressing p53 in humans through the SV40 large T-antigen and SV40 small T-antigen. It is generally assumed that large T-antigen is the major protein involved in neoplastic processes and the large T-antigen predominantly exerts its effect through deregulation of tumor suppressor p53, which is responsible for initiating regulated cell death (apoptosis), or cell cycle arrest when a cell is damaged. A mutated p53 gene may contribute to uncontrolled cellular proliferation, leading to a tumor.
Antibody Isotype:
IgG2a
Monosan Range:
MONOSAN Ready To Use
Clone:
MRQ-4
Concentration:
n/a
Storage buffer:
Tris Buffer, pH 7.3-7.7, containing 1% BSA and <0.1% Sodium Azide
Storage:
2-8°C
References 1:
Gurney, E.G., et al. J Virl. 34:752-763 (1980)
References 2:
Huang, H., Reis,R. et al. Brain Pathol., 9:33-42 (1999)
References 3:
Arrington, A.S., et al. Molecular and Clinical Perspectives; 461-489 (2001)
The monoclonal antibody T2.5 recognizes human Toll-like receptor 2 (TLR2). Toll-like receptors (TLR) are highly conserved throughout evolution and have been implicated in the innate defense to many pathogens. At present, ligands for several of the TLR's, such as TLR2-6,9, have been identified, confirming their role in first line defense against invading microorganism. In mammals, TLRs are identified as type I transmembrane signaling receptors with an extracellular portion containing leucine-rich repeats with pattern recognition capabilities. Pathogen recognition by TLRs provokes rapid activation of innate immunity by inducing proliferation of proinflammatory cytokines and upregulation of costimulatory molecules and eventually toinitiation of adaptive immunity. TLR2 has been identified as a receptor that is central to the innate immune response to lipoproteins of Gram-negative bacteria, several whole Gram-positive bacteria, as well as a receptor for peptidoglycan and lipoteichoic acid and other bacterial cell membrane products. It is suggested that TLR2 is able to recognize such a wide variety of PAMPs (pathogen-specific molecular patterns) by forming heterodimers with other TLRs like e.g. TLR6. TLR2 is essential for recognizing lipopeptides and lipoproteins from several microorganisms and also peptidoglycans derived from gram-positive bacteria. Bacterial species as diverse as mycobacteria, spirochetes, mycoplasma, Staphylococcus aureus, and Streptococcus pneumoniae have all been shown to mediate cellular activation via TLR2.
Toll-like receptors (TLRs) are highly conserved from Drosophila to humans and share structural and functional similarities. TLRs constitute of a family of pattern recognition receptors (PRRs) that mediate cellular responses to a large variety of pathogens (viruses, bacteria, and parasites) by specific recognition of so-called âpathogen-associated molecular patternsâ. Activation of TLRs, a family of at least 11 different members that function either as homo- or heterodimers, leads to activation of NFκB-dependent and IFN-regulatory factor-dependent signaling pathways. TLRs have a central role in innate immunity and are also required for the development of an adaptive immune response. TLRs are expressed by various cells of the immune system, such as macrophages and dendritic cells. TLRs are class I receptors, with a single ?-helix that spans the cell membrane. They recognize and respond to molecules derived from bacterial, viral and fungal pathogens, such as lipopolysaccharide (LPS) from the outer membrane of Gram negative bacteria, peptidoglycan fragments from bacterial cell walls and single-stranded and double-stranded RNA from viruses. Toll-like receptor 4 (TLR4; CD284) has been identified, next to MD-2 and CD14, as a receptor that is central to the innate immune response to LPS of Gram-negative bacteria. TLR4 is unique among TLRs in its ability to activate two distinct signaling pathways; one pathway is activated by the adaptors TIRAP (Toll/interleukin-1- receptor (TIR)-domain-containing adaptor protein) and MyD88, which leads to the induction of proâinflammatory cytokines. The second pathway is activated by the adaptors TRIF (TIR-domaincontaining adaptor protein inducing interferonâβ) and TRAM (TRIFrelated adaptor molecule), which leads to the induction of type I interferons. The monoclonal antibody HTA125 is a TLR4 function-blocking antibody. HTA125 recognizes preferentially human TLR4 that is associated with MD-2.
Antibody Isotype:
IgG2a
Monosan Range:
MONOSAN
Clone:
HTA125
Concentration:
100 ug/ ml
Storage buffer:
PBS with 0.1% BSA and 0.02% sodium azide
Storage:
2-8°C
References 1:
Shimazu; R et al. J Exp Med 1999; 189: 1777
References 2:
Tabeta, K et al Infect Immun 2000, 68: 3731
References 3:
Akashi; S et al. Biochem Biophys Res Commun 2000; 268: 172
The monoclonal antibody 5G5 reacts with the Toll-like receptor 9 (TLR9, CD289). TLRs are highly conserved throughout evolution and have been implicated in the innate defence to many pathogens. In Drosophila, toll is required for the anti-fungal response, while the related 18-wheeler is involved in antibacterial defences. In mammals, TLRs identified as type I transmembrane signalling receptors with pattern recognition capabilities, have been implicated in the innate host defence to pathogens. As investigated so far all functional characterized TLR signal via the TLR/IL-1 receptor (IL-1R) pathway where recruitment of MyD88 seems to be essential. In contrast to cell-wall components, bacterial DNA is probably invisible for immune cells until DNA is liberated during processes taking place in the endosomal/lysosomal compartment where intracellular TLR9 recruits MyD88 to initiate signal transduction. Unmethylated CpG-dinucleotide-containing sequences are found much more frequently in bacterial genomes than in vertebrates genomes, whereas the frequency of CpG dinucleotides are suppressed and usually methylated. The regions adjacent to the CpG dinucleotides also affect the immunostimulatory activity. The optimal sequence differs significantly between mammalian species. Methylated CpG dinucleotides lack immunostimulatory activities. Cellular activation in response to bacterial DNA and synthetic dinucleotides containing unmethylated CpG-dinucleotides is mediated by TLR9. The monoclonal antibody 5G5 reacts with RAW macrophages and TLR9 transfected HEK293 cells, and it is cross reactive with canine TLR9.
Antibody Isotype:
IgG2a
Monosan Range:
MONOSAN
Clone:
5G5
Concentration:
100 ug/ ml
Storage buffer:
PBS with 0.1% BSA and 0.02% sodium azide
Storage:
2-8°C
References 1:
Ahmad-Nejad; P et al. Eur J Immunol 2002; 32: 1958
The monoclonal antibody 5G5 recognizes human Toll-like receptor 9. Toll-like receptors (TLRs) are highly conserved from Drosophila to humans and share structural and functional similarities. TLRs constitute of a family of pattern recognition receptors (PRRs) that mediate cellular responses to a large variety of pathogens (viruses, bacteria, and parasites) by specific recognition of so-called âpathogen-associated molecular patternsâ. Activation of TLRs, a family of at least 11 differentmembers that function either as homo- or heterodimers, leads to activation of NFκB-dependent and IFNregulatory factor-dependent signaling pathways. TLRs have a central role in innate immunity and are also required for the development of an adaptive immune response. TLRs are expressed by various cells of the immune system, such as macrophages and dendritic cells. They recognize and respond to molecules derived from bacterial, viral and fungal pathogens.<br /> Whereas most TLRs are expressed on the cell surface, TLR9 is expressed intracellularly within one or more endosomal compartments and recognizes nucleic acids. TLR9 detects a rather subtle difference in the DNA of vertebrates compared with that of pathogens. Vertebrate genomic DNAs have mostly methylated CpG dinucleotides where bacterial and viral DNAs have unmethylated CpG dinucleotides. TLR9 undergoes relocation from endoplasmic reticulum to CpG-ODN-containing endosomes. In these endosomes TLR9 becomes a functional receptor after proteolytic cleavage. TLR9 exists as a preformed homodimer and CpG-ODN binding promotes its conformational change, bringing the cytoplasmic TIR-like domains close to each other. This allows a recruitment of the key adapter protein MyD88 which initiates a signalling cascade. The only human immune cell types known to constitutively express TLR9 and to be activated by CpG ODN are pDCs and B cells. TLR9 triggering induces an activation phenotype in the B cells and pDCs, characterized by the expression of costimulatory molecules, resistance to apoptosis, and induces Th1-type immune response profiles.
Antibody Isotype:
IgG2a
Monosan Range:
MONOSAN
Clone:
5G5
Concentration:
100 ug/ ml
Storage buffer:
PBS with 0.1% BSA and 0.02% sodium azide
Storage:
2-8°C
References 1:
Ahmad-Nejad; P et al. Eur J Immunol 2002; 32: 1958
UACA (Uveal Autoantigen with Coiled-coil domains and Ankyrin repeats) is a 1,416 amino acid nuclear membrane protein. It was originally identified as an autoantigen in patients with panuveitis, a characteristic of Vogt-Koyanagi-Harada disease, and in patients with Graves' disease. UACA was also later identified as Nucling, a mRNA differentially expressed in F9 embryonal carcinoma cells, and that is up-regulated during cardiac muscle differentiation. UACA appears to function as a pro-apoptotic protein that recruits the apaf-1- pro-caspase-9 complex for the induction of apoptosis to mediate the cell-death pathway.
Antibody Isotype:
IgG1-K
Monosan Range:
MONOSAN
Clone:
AE-5
Concentration:
100 ug/ml
Storage buffer:
PBS with 0.02% sodium azide
Storage:
2-8°C
References 1:
Yamada, K., et al. Biochem. Biophys. Res. Commun. 280: 1169-1176 (2001)
Apolipoprotein A5 (ApoA5) is fast gaining attention as a key regulator of serum triglyceride concentrations. An ApoA5 mouse knock-out model produced an approximately four fold increase in serum triglycerides, whereas a knock-in model with human ApoA5 produced 5070% lower ; concentrations of mouse serum triglycerides. In addition, peroxisome proliferator-activated receptor-_ agonists, which are used clinically to lower serum triglyceride concentrations, cause increased ApoA5 mRNA expression. Recently, it was demonstrated that ApoA5 is present in human serum detected by polyclonal antibodies against both the NH2 and COOH termini, although at much lower concentration than other apolipoproteins.
Product Type:
Antibodies Primary
Antibody Type:
monoclonal
Storage Temp:
4°C -20°C for long term storage
Host Animal:
mouse
Immunogen:
Purified recombinant fragment of human APOA5 (AA: 20-363) expressed in E. Coli.
X
We use cookies to help personalise and improve your web experience.
By using our website you consent to our use of cookies, some of which may have already been set on your device.
View our Cookie Policy to learn more.
